Ocular drug delivery market seen reaching $29.44 billion by 2030

The Business Research Company says the ocular drug delivery market is on track to grow from $19.16 billion in 2025 to $29.44 billion by 2030, driven by aging populations, chronic eye disease and new delivery technologies. North America led the market in 2025, while Asia-Pacific and other emerging economies are expected to grow fastest.

Why it matters: - Ocular drug delivery is becoming more important as eye diseases rise with age and treatments shift toward targeted, localized therapy. - The market's expected growth signals more demand for long-acting treatments, better adherence and technologies that improve drug delivery to the eye.

What happened: - The Business Research Company said the global ocular drug delivery market was valued at $19.16 billion in 2025. - The market is projected to reach $20.81 billion in 2026 and $29.44 billion by 2030. - The forecast implies an 8.6% CAGR in the historic period and 9.1% CAGR through 2030. - The company published the outlook from London on Aug. 20, 2026. - The release included a free sample report and a full market report.

The details: - Ocular drug delivery means administering medication directly to parts of the eye to treat eye disease. - The approach can improve drug concentration at the target site, raise bioavailability and reduce systemic side effects. - The market's historical growth was driven by higher rates of glaucoma and retinal disorders, demand for localized eye treatments, advances in ophthalmic formulations, more specialized ophthalmology clinics and better understanding of ocular pharmacokinetics. - Future growth is expected to come from long-acting ocular therapies, an aging population with chronic eye conditions, more funding for ophthalmic research and development, advanced ocular implant technologies and a stronger focus on adherence and outcomes. - Emerging trends include sustained-release ocular implants, nanoparticle-based delivery systems, targeted retinal therapies, minimally invasive delivery platforms and improved drug bioavailability. - North America held the largest market share in 2025. - Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa are included in the report's regional coverage. - Asia-Pacific and other emerging economies are expected to grow faster as healthcare access improves and eye disease prevalence rises. - The report also highlights enhanced strategic insights, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

Between the lines: - The forecast suggests the category is moving beyond conventional eye drops and toward longer-acting, more precise delivery systems. - The emphasis on adherence and outcomes points to a market shaped by chronic disease management, not just one-time treatment. - Population aging remains the clearest structural tailwind, with the number of Americans 65 and older projected to rise from 58 million in 2022 to 82 million by 2050, according to the Population Reference Bureau.

What's next: - The market's next phase will likely center on sustained-release devices, targeted therapies and delivery platforms that can improve convenience for patients with chronic eye conditions. - Regional growth is likely to stay strongest in markets where healthcare access is expanding and eye disease burden is increasing. - The Business Research Company positioned its updated report as a tool for tracking forecasts and identifying market hotspots.